Literature DB >> 20413324

Insights into amylin-leptin synergy.

James L Trevaskis1, David G Parkes, Jonathan D Roth.   

Abstract

Although the adipokine leptin is regarded as the prototypical long-term signal of energy balance, obese individuals are largely nonresponsive to exogenous leptin administration. Restoration of leptin responsiveness in obesity has been elusive despite a detailed understanding of the molecular mechanisms of leptin signaling. Recent translational research findings point to a potential therapeutic approach that incorporates amylin (a beta-cell hormone) and leptin agonism, with amylin restoring or enhancing leptin sensitivity. Here we hypothesize various physiological, neurobiological and molecular mechanisms that could mediate the interaction of these two neurohormonal signals and discuss several methodological challenges. Understanding how amylin agonism improves leptin function could point to general therapeutic strategies for combating leptin resistance and associated obesity. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413324     DOI: 10.1016/j.tem.2010.03.006

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  28 in total

1.  Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes.

Authors:  R J Bailey; C S Walker; A H Ferner; K M Loomes; G Prijic; A Halim; L Whiting; A R J Phillips; D L Hay
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  20 years of leptin: role of leptin in energy homeostasis in humans.

Authors:  Michael Rosenbaum; Rudolph L Leibel
Journal:  J Endocrinol       Date:  2014-07-25       Impact factor: 4.286

Review 3.  Could the mechanisms of bariatric surgery hold the key for novel therapies? report from a Pennington Scientific Symposium.

Authors:  C S Tam; H-R Berthoud; M Bueter; M V Chakravarthy; A Geliebter; A Hajnal; J Holst; L Kaplan; W Pories; H Raybould; R Seeley; A Strader; E Ravussin
Journal:  Obes Rev       Date:  2011-07-06       Impact factor: 9.213

Review 4.  GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Authors:  Jonathan D Roth; Mary R Erickson; Steve Chen; David G Parkes
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 5.  Amylin-mediated control of glycemia, energy balance, and cognition.

Authors:  Elizabeth G Mietlicki-Baase
Journal:  Physiol Behav       Date:  2016-02-27

Review 6.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 7.  Novel strategy for the use of leptin for obesity therapy.

Authors:  Charmaine S Tam; Virgile Lecoultre; Eric Ravussin
Journal:  Expert Opin Biol Ther       Date:  2011-09-13       Impact factor: 4.388

Review 8.  Control of energy homeostasis by amylin.

Authors:  Thomas A Lutz
Journal:  Cell Mol Life Sci       Date:  2011-12-23       Impact factor: 9.261

Review 9.  Islet amyloid: from fundamental biophysics to mechanisms of cytotoxicity.

Authors:  Ping Cao; Peter Marek; Harris Noor; Vadim Patsalo; Ling-Hsien Tu; Hui Wang; Andisheh Abedini; Daniel P Raleigh
Journal:  FEBS Lett       Date:  2013-02-01       Impact factor: 4.124

Review 10.  Mechanisms of islet amyloidosis toxicity in type 2 diabetes.

Authors:  Andisheh Abedini; Ann Marie Schmidt
Journal:  FEBS Lett       Date:  2013-01-18       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.